Benjamine Liu, Formation Bio co-founder and CEO
June 26, 2024 09:00 AM EDT
Financing
AI

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Andrew Dunn

Senior Biopharma Correspondent

While the bulk of AI-fo­cused biotechs try to dis­cov­er drugs and push the bound­aries of bi­ol­o­gy, Ben­jamine Liu would rather syn­the­size meet­ing min­utes than mol­e­cules …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times